Eli Lilly, Evidation Health expand data analysis collaboration

Eli Lilly and Co., a drug manufacturer, and Evidation Health, a health and behavior measurement company, entered into a multiyear agreement that grants Lilly global access to Evidation's Andromeda data platform.

Per the agreement, Lilly's scientists and researchers will have access to Evidation's data platform, helping them measure and understand patient behavior with regard to their health. They will have access to consented data derived from smartphones, connected sensors, wearables and the patient's own voice.

Lilly's research teams will also be able to use Evidation-built algorithms to process raw data for use in clinical studies or to create predictive models.

"Our initial collaborations with Lilly demonstrated that digital biomarkers can play a significant role in understanding individuals and disease, and we are excited to expand our collaboration," said Christine Lemke, co-founder and president of Evidation.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars